For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Everolimus | Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity everolimus laboratory biomarker analysis | None | None | 24 | 47 | 47 | 47 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Mucositis | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v3 | View |
| Anorexia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v3 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hyperglycemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hyperlipidemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Alkaline phosphatase | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| ALT | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Anorexia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v3 | View |
| AST | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | NCI CTCAE v3 | View |
| Bloating | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Bronchospasm | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v3 | View |
| Cachexia | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Cardiac Infarction | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v3 | View |
| Cardiopulmonary Arrest | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v3 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v3 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Distension | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v3 | View |
| Dry Mouth | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Dry skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Dyspnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v3 | View |
| Ecchymosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Edema - limb | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Fever | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v3 | View |
| Flatulence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Halitosis | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Hemorrhage pulmonary - nose | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | NCI CTCAE v3 | View |
| Hemorrhage, GI - abdomen NOS | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v3 | View |
| Hot flashes | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Hypercholesteremia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hyperglycemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hyperlipidemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hypertriglyceridemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hypocalcemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hypokalemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v3 | View |
| Infection - Kidney | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v3 | View |
| Infection - Lung | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v3 | View |
| Infection - urinary tract NOS | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v3 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| LDL - elevated | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Leukopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Lymphopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Mood alteration - anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v3 | View |
| Mood alteration - depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v3 | View |
| Mucositis - oral cavity | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v3 | View |
| Muscle weakness - generalized | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Nasal/paranasal reactions | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v3 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Neuropathy-sensory | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Pain - abdomen | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - back | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - body | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - chest/thorax NOS | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - extremity-limb | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - eye | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - head | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - hip | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - NOS | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - oral cavity | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - shoulder | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Pain - Stomach | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Pain - throat | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v3 | View |
| Performance status decrease | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Pneumonitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v3 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v3 | View |
| Stomatitis | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v3 | View |
| Sweating | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v3 | View |
| Taste alteration | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v3 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v3 | View |
| Weakness | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |
| Weight loss | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v3 | View |